Ribociclib

Ribociclib
Clinical data
Trade names	Kisqali
Other names	LEE 011
AHFS/Drugs.com	Monograph
MedlinePlus	a617008
License data	US DailyMed: Ribociclib;
Routes of; administration	By mouth
Drug class	Antineoplastic, CDK inhibitor
ATC code	L01EF02 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Bioavailability	Unknown
Protein binding	~70%
Metabolism	Liver (CYP3A4)
Elimination half-life	32.0 (29.7–54.7) hrs
Excretion	69% feces, 23% urine
Identifiers
	IUPAC name 7-Cyclopentyl-N,N-dimethyl-2-{[5-(1-piperazinyl)-2-pyridinyl]amino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide;
CAS Number	1211441-98-3;
PubChem CID	44631912;
DrugBank	DB11730;
ChemSpider	30798107;
UNII	TK8ERE8P56;
KEGG	D10883; as salt: D10979;
ChEMBL	ChEMBL3545110;
CompTox Dashboard (EPA)	DTXSID201021027 ;
ECHA InfoCard	100.234.566
Chemical and physical data
Formula	C23H30N8O
Molar mass	434.548 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN(C)C(=O)c1cc2cnc(nc2n1C3CCCC3)Nc4ccc(cn4)N5CCNCC5;
	InChI InChI=1S/C23H30N8O/c1-29(2)22(32)19-13-16-14-26-23(28-21(16)31(19)17-5-3-4-6-17)27-20-8-7-18(15-25-20)30-11-9-24-10-12-30/h7-8,13-15,17,24H,3-6,9-12H2,1-2H3,(H,25,26,27,28); Key:RHXHGRAEPCAFML-UHFFFAOYSA-N;

Ribociclib, sold under the brand name Kisqali, is a medication used for the treatment of certain kinds of breast cancer. Ribociclib is a kinase inhibitor. It was developed by Novartis and Astex Pharmaceuticals.

The most common side effects include infections, low levels of white blood cells, headache, cough, nausea (feeling sick), vomiting, diarrhea, constipation, tiredness, hair loss and rash.

Ribociclib was approved for medical use in the United States in March 2017, in the European Union in August 2017, and in the United Kingdom in February 2021.